F10 and atrial fibrillation: Recent studies have proposed the uninterrupted use of DOACs with a temporary switch to dabigatran (“dabigatran bridge”) in patients undergoing AF ablation and taking factor Xa inhibitors.10, 11 This OAC strategy seems to compensate for the drawbacks of the uninterrupted use of factor Xa inhibitors in the absence of andexanet alfa.